These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37555516)

  • 1. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline.
    Boccalini C; Ribaldi F; Hristovska I; Arnone A; Peretti DE; Mu L; Scheffler M; Perani D; Frisoni GB; Garibotto V
    Alzheimers Dement; 2024 Jan; 20(1):221-233. PubMed ID: 37555516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.
    Dowling NM; Johnson SC; Gleason CE; Jagust WJ;
    Neuroimage; 2015 Jan; 105():357-68. PubMed ID: 25450107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease.
    Tanner JA; Iaccarino L; Edwards L; Asken BM; Gorno-Tempini ML; Kramer JH; Pham J; Perry DC; Possin K; Malpetti M; Mellinger T; Miller BL; Miller Z; Mundada NS; Rosen HJ; Soleimani-Meigooni DN; Strom A; La Joie R; Rabinovici GD
    Brain; 2022 Dec; 145(12):4489-4505. PubMed ID: 35762829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
    Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
    JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients.
    Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Zetterberg H; Abramowicz M; Scheffler M; Assal F; Garibotto V; Blennow K; Frisoni GB
    Alzheimers Res Ther; 2024 May; 16(1):110. PubMed ID: 38755703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suspecting Non-Alzheimer's Pathologies and Mixed Pathologies: A Comparative Study Between Brain Metabolism and Tau Images.
    Malotaux V; Colmant L; Quenon L; Huyghe L; Gérard T; Dricot L; Ivanoiu A; Lhommel R; Hanseeuw B
    J Alzheimers Dis; 2024; 97(1):421-433. PubMed ID: 38108350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic and prognostic value of tau-PET in amnestic MCI with different FDG-PET subtypes.
    Boccalini C; Caminiti SP; Chiti A; Frisoni GB; Garibotto V; Perani D;
    Ann Clin Transl Neurol; 2024 May; 11(5):1236-1249. PubMed ID: 38553802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset.
    Altomare D; Ferrari C; Caroli A; Galluzzi S; Prestia A; van der Flier WM; Ossenkoppele R; Van Berckel B; Barkhof F; Teunissen CE; Wall A; Carter SF; Schöll M; Choo ILH; Grimmer T; Redolfi A; Nordberg A; Scheltens P; Drzezga A; Frisoni GB;
    J Neurol; 2019 Oct; 266(10):2535-2545. PubMed ID: 31267207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
    Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
    Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
    Gordon BA; Blazey TM; Christensen J; Dincer A; Flores S; Keefe S; Chen C; Su Y; McDade EM; Wang G; Li Y; Hassenstab J; Aschenbrenner A; Hornbeck R; Jack CR; Ances BM; Berman SB; Brosch JR; Galasko D; Gauthier S; Lah JJ; Masellis M; van Dyck CH; Mintun MA; Klein G; Ristic S; Cairns NJ; Marcus DS; Xiong C; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
    Brain; 2019 Apr; 142(4):1063-1076. PubMed ID: 30753379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
    Malpetti M; Kievit RA; Passamonti L; Jones PS; Tsvetanov KA; Rittman T; Mak E; Nicastro N; Bevan-Jones WR; Su L; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2020 May; 143(5):1588-1602. PubMed ID: 32380523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline.
    Bucci M; Chiotis K; Nordberg A;
    Mol Psychiatry; 2021 Oct; 26(10):5888-5898. PubMed ID: 34593971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
    Biel D; Luan Y; Brendel M; Hager P; Dewenter A; Moscoso A; Otero Svaldi D; Higgins IA; Pontecorvo M; Römer S; Steward A; Rubinski A; Zheng L; Schöll M; Shcherbinin S; Ewers M; Franzmeier N;
    Alzheimers Res Ther; 2022 Nov; 14(1):166. PubMed ID: 36345046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically identical twin-pair difference models support the amyloid cascade hypothesis.
    Coomans EM; Tomassen J; Ossenkoppele R; Tijms BM; Lorenzini L; Ten Kate M; Collij LE; Heeman F; Rikken RM; van der Landen SM; den Hollander ME; Golla SSV; Yaqub M; Windhorst AD; Barkhof F; Scheltens P; de Geus EJC; Visser PJ; van Berckel BNM; den Braber A
    Brain; 2023 Sep; 146(9):3735-3746. PubMed ID: 36892415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Cody KA; Langhough RE; Zammit MD; Clark L; Chin N; Christian BT; Betthauser TJ; Johnson SC
    Brain; 2024 Jun; 147(6):2144-2157. PubMed ID: 38667631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease.
    Halawa OA; Gatchel JR; Amariglio RE; Rentz DM; Sperling RA; Johnson KA; Marshall GA;
    Alzheimers Res Ther; 2019 Jan; 11(1):14. PubMed ID: 30704519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum.
    Tosun D; Demir Z; Veitch DP; Weintraub D; Aisen P; Jack CR; Jagust WJ; Petersen RC; Saykin AJ; Shaw LM; Trojanowski JQ; Weiner MW;
    Alzheimers Dement; 2022 Jul; 18(7):1370-1382. PubMed ID: 34647694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.